Effectiveness of Vonoprazan on Health-Related Quality of Life and Sleep Quality in Chinese Patients With Reflux Esophagitis: Post Hoc Analysis of the VIEW Study
Author(s)
Yinglian Xiao, PhD1, Kailun Liang, MSc2, Fang Zhou, MSc2, Minhu Chen, PhD1.
1The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, 2Takeda Pharmaceutical Company, Shanghai, China.
1The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, 2Takeda Pharmaceutical Company, Shanghai, China.
OBJECTIVES: Reflux esophagitis (RE), a phenotype of gastroesophageal reflux disease, can negatively impact patients’ quality of life. The objective of this analysis was to evaluate the effectiveness of vonoprazan treatment on health-related quality of life (HRQoL) and sleep quality in Chinese patients with RE in a real-world clinical setting.
METHODS: VIEW (NCT04501627) was a multicenter, single-arm, prospective, observational study conducted in China. Enrolled patients received 20 mg of vonoprazan once daily for 4 weeks (8 weeks if insufficient benefit). This post hoc analysis assessed the changes from baseline to Week 4 in the EuroQol 5-Dimension 5-Level (EQ-5D-5L, for HRQoL) and the Pittsburgh Sleep Quality Index (for sleep quality) scores.
RESULTS: Among the 1877 patients included in the RE safety analysis population, the mean (standard deviation) age and body mass index were 49.7 (13.4) years and 24.1 (3.5) kg/m2, respectively. Compared with those at baseline, significant differences in the distribution of EQ-5D-5L dimension levels for pain/discomfort and anxiety/depression (P<0.001 for both) were observed at Week 4. The percentage of patients with no pain/discomfort and no anxiety/depression increased from 47.8% to 69.4% and 64.6% to 77.7%, respectively. Among the 721 patients with poor sleep quality at baseline, the proportion of patients with improved sleep quality at Week 4 and with complete relief (symptom score=0 [from Days 1-7]) from nighttime regurgitation during the first week was significantly greater than those with incomplete relief (26.2% vs 14.9%, P=0.001). Similar trends in sleep quality improvement, although nonsignificant, were observed with a higher proportion of patients with complete relief vs incomplete relief from heartburn and regurgitation (25.0% vs 16.5%, P=0.094) and from nighttime heartburn (22.1% vs 15.9%, P=0.070) at Week 4.
CONCLUSIONS: Vonoprazan treatment in real-world clinical practice improved HRQoL and sleep quality among Chinese patients with RE.
METHODS: VIEW (NCT04501627) was a multicenter, single-arm, prospective, observational study conducted in China. Enrolled patients received 20 mg of vonoprazan once daily for 4 weeks (8 weeks if insufficient benefit). This post hoc analysis assessed the changes from baseline to Week 4 in the EuroQol 5-Dimension 5-Level (EQ-5D-5L, for HRQoL) and the Pittsburgh Sleep Quality Index (for sleep quality) scores.
RESULTS: Among the 1877 patients included in the RE safety analysis population, the mean (standard deviation) age and body mass index were 49.7 (13.4) years and 24.1 (3.5) kg/m2, respectively. Compared with those at baseline, significant differences in the distribution of EQ-5D-5L dimension levels for pain/discomfort and anxiety/depression (P<0.001 for both) were observed at Week 4. The percentage of patients with no pain/discomfort and no anxiety/depression increased from 47.8% to 69.4% and 64.6% to 77.7%, respectively. Among the 721 patients with poor sleep quality at baseline, the proportion of patients with improved sleep quality at Week 4 and with complete relief (symptom score=0 [from Days 1-7]) from nighttime regurgitation during the first week was significantly greater than those with incomplete relief (26.2% vs 14.9%, P=0.001). Similar trends in sleep quality improvement, although nonsignificant, were observed with a higher proportion of patients with complete relief vs incomplete relief from heartburn and regurgitation (25.0% vs 16.5%, P=0.094) and from nighttime heartburn (22.1% vs 15.9%, P=0.070) at Week 4.
CONCLUSIONS: Vonoprazan treatment in real-world clinical practice improved HRQoL and sleep quality among Chinese patients with RE.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR67
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Gastrointestinal Disorders